Boston Therapeutics' BTI-320 in Clinical Trial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Boston Therapeutics' BTI-320 in Clinical Trial Significantly Reduces Both Glucose and Fructose Levels in Blood

MANCHESTER, NH--(Marketwired - Sep 15, 2015) - Boston Therapeutics, Inc. ( OTCQB : BTHE ) today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd. (APC), is conducting a clinical trial at The Chinese University of Hong Kong (CUHK) to evaluate BTI-320 in subjects who are pre-diabetic. The clinical trial has enrolled 56 of the planned 60 pre-diabetic patients. Also, the interim clinical analysis in the proof of concept trial demonstrate up to 77% reduction in Glucose and up to 27% in Fructose.

This key developmental trial and the associated endpoints are pivotal for concluding the BTI-320 registration in mainland China. The pivotal trial for product registration will enter the final phase for registration through testing this month 2015. The clinical trial is planned to be completed by year end and the overall dossier for approval is targeted to be submitted in January 2016 for pending country wide approval in the first half of 2016. BTI-320 is planned to address and benefit a population of 495,000,000 million pre-diabetic people in China ( JAMA . 2013 Sep 4;310(9):948-59 ) and 50% of the entire population in the USA, who are pre-diabetic and diabetic ( JAMA . 2015;314(10):1021-1029 ) and could make a significant contribution to controlling healthcare costs.

Enrollment in the CUHK trial is on track to conclude by November 2015 and is expected to confirm the assessment of prevention biomarker parameters associated with postprandial glucose (PPG) spikes, Fructose accumulation (Fructosamine blood testing) and PPG maximum amplitude peaking and Fructosamines appears to be a major detrimental aspect and predicament to lowering HbA1c and forestalling the onset and the advancement of type 2 Diabetes without the hypoglycemic threat possible with many of the treatment compounds presently associated with diabetes treatment.

The Chinese FDA process is a major focus of APC's alliance partnership in Asia, where they are piloting clinical marketing education programs, specifically in Korea, Hong Kong, Singapore, and most recently Japan.

David Platt, Ph.D., CEO of Boston Therapeutics, said, "BTI-320 is the only drug candidate in development to block Glucose and Fructose and other sugars simultaneously. We are fortunate to have APC as a financial partner to conduct and fund these and other studies and look forward to commercializing BTI-320 where we may help many people to manage this world health mandate to manage blood sugar."

Boston Therapeutics developed BTI-320 and markets it through APC in Asia. BTI-320 is a non-systemic chewable compound designed to reduce post-meal elevation of blood Glucose, Fructose and other key Sugars. BTI-320 is to be taken before meals and works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down complex carbohydrates into simple sugars, reducing the availability of glucose Fructose and other sugars for absorption into the bloodstream.

The single-center, 16-week, randomized, double-blind, placebo-controlled, three-treatment arm pilot trial is designed to evaluate the tolerability, safety and efficacy of BTI-320 in high-risk Chinese subjects with pre-diabetes. The primary endpoint is change in serum Fructosamine in subjects treated with low-dose BTI-320 and high-dose BTI-320 compared with placebo from baseline to Week 4. The secondary endpoints include changes in Area Under the Curve (AUC) and HbA1c in subjects treated with low-dose BTI-320 and high-dose BTI-320 compared with placebo from baseline to Week 4 and Week 16. A total of 60 subjects are expected to be recruited for the trial.

Dr. Juliana CN Chan, PRCP is the lead principal investigator and the lead clinical site is the Department of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital.

Obesity and Fructose/ Serum Fructosamine Obesity is a major epidemic and excessive consumption of high-fructose corn syrup (HFCS) in beverages plays a role. The consumption of HFCS increased dramatically in the last several decades. Today, HFCS represents a significant portion of caloric sweeteners added to foods and beverages and is a caloric sweetener used in soft drinks. Sucrose is one part glucose and one part fructose. These are two "sugars," one the body uses for energy and the other is made into fat if not utilized and converted into glucose. The digestion, absorption, and metabolism of fructose differs from the metabolism of glucose. In addition, unlike glucose, fructose does not stimulate insulin secretion or enhance leptin production (the hormone that signals us to stop eating). Because insulin and leptin act as key afferent signals in the regulation of food intake and body weight, this suggests that fructose may contribute to increased energy intake and weight gain. Furthermore, calorically sweetened beverages may enhance caloric overconsumption. Thus, the increase in consumption of HFCS has a temporal relation to the epidemic of obesity, and the overconsumption of HFCS in calorically sweetened beverages may play a role in the epidemic of obesity.

BTI-320 is being administered as an oral chewable tablet containing either four grams of BTI-320 or matching placebo. All subjects are instructed to take two chewable tablets prior to meal ingestion. Low-dose BTI-320 consists of one active chewable tablet and one placebo chewable tablet; high-dose BTI-320 consists of two active chewable tablets.

About Advance Pharmaceutical Company, Ltd.

Advance Pharmaceutical Company is a leading Hong Kong-based pharmaceutical company. Advance Pharmaceutical Company currently sells more than 400 types of licensed pharmaceutical products, consisting of prescription and over the counter products to local dispensaries, medicine shops, clinics and hospitals, as well as chain stores, such as 7-11, Wellcome, Park-N-Shop, Mannings and Watson's. Outside of Hong Kong, Advance Pharmaceutical Company has been building and maintaining its marketing network in Macau since 1983 and has many years of experience in exporting and distributing pharmaceutical products to China. Currently, Advance Pharmaceutical Company's products penetrate 90% of dispensaries and drug stores in Macau. Additional information is available at http://www.apc.com.hk/aboutus.php .

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, ( OTCQB : BTHE ) is an innovator in designing compounds using complex carbohydrate chemistry. The company's product pipeline is focused on developing and commercializing therapeutic molecules that address diabetes and inflammatory diseases, including: BTI-320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug designed initially to treat lower limb ischemia associated with diabetes. More information is available at www.bostonti.com and www.clinicaltrials.gov .

Cautionary Note Regarding Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "May," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others that our plans, expectations and goals regarding our clinical development of BTI-320 are subject to factors beyond our control. We can provide no assurance that we or our commercial partners will be able to generate market demand for BTI-320, and thus we may not be able to generate revenue from sales.

Moreover, we have incurred operating losses since our inception, and our ability to successfully develop, market, manufacture, distribute and sell drugs or over-the-counter products may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional risk and other factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2014, and our subsequent filings with the SEC.

You should not place undue reliance on forward-looking statements, and actual results may differ materially from the results anticipated in our forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

© Boston Therapeutics, Inc. All rights reserved.

Contact: Boston Therapeutics, Inc. David Platt, PhD Chief Executive Officer Phone: 603-935-9799 Email: david.platt@bostonti.com www.bostonti.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 157

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
HashKey and Base Aim to Bridge Asia With Liquidity

Updated Category News Views 79

A blockchain partnership can sound like confetti until the plumbing matters. This one at least points at a real commercial choke point: Asian-originated tokenized assets need deeper pools of global onchain capital, while global networks need credible asset supply and institutional access. HashKey Group's HSK Chain and Coinbase-built Base say they intend to tackle both...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 91

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading
Charter’s $1.5 Billion Tender Tests Debt Discipline

Updated Category News Views 227

Debt cleanup arrives with a hard ceiling Eight far-dated bond issues just got a very specific invitation from Charter Communications: hand them over for cash, but do not expect the company to write a blank check. Charter set final pricing on November 17 for tender offers covering up to $1.5 billion in aggregate consideration, excluding accrued interest and deal expenses....

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 257

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Azazie Tests Bridal Demand With Two East Coast Pop-Ups

Updated Category News Views 127

Wedding dresses are a miserable product to buy sight unseen, no matter how pretty the product photos look. That basic fact is why Azazie’s two East Coast pop-ups on November 21 and 22 deserve a closer look. This is not some grand retail rollout, and nobody should pretend a pair of short events rewrites the bridal market. But it is a practical test of where a...

Continue Reading
Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 25

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 159

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Markel Elevates War Risk Expertise in London Market

Updated Category News Views 42

A Specialty Desk Gets Its Own Weather Vane War and political violence underwriting is not a corner of insurance where a fancy title change can be shrugged off. The ground shifts under the policyholder, the broker and the carrier without much warning, and a bad call can sit on a book for years. Markel Insurance has named Chloe Gordge Director of War and Political Violence...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 182

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading

Top 5 Most Recently Viewed Articles

TRUBAR Inc. Takes Bold Steps with Personal Care Product Sale

Updated Category News Views 169

TRUBAR Inc. Streamlines Focus with Recent Asset Sale TRUBAR Inc. is making significant moves to streamline its operations and focus on its core identity as a leading provider of plant-based protein products. The company has announced that it has successfully sold the assets related to its personal care product line through its subsidiary, NO BS Life, LLC. This strategic...

Continue Reading
Advancements in Squamous Cell Carcinoma Treatments Unveiled

Updated Category News Views 362

Examining Treatments for Squamous Cell Carcinoma The landscape of squamous cell carcinoma (SCC) treatments is rapidly evolving. This shift is largely driven by the increasing number of diagnosed cases. As public awareness rises and exposure to risk factors like ultraviolet (UV) radiation continues, healthcare professionals and researchers are persistently seeking...

Continue Reading
Millennium Physician Group and IMA Medical Group Unite for Better Care

Updated Category News Views 327

Millennium Physician Group and IMA Medical Group Unite for Better Patient Care In an exciting development for healthcare in Central Florida, Millennium Physician Group has announced its collaboration with IMA Medical Group. This partnership represents a major step forward in expanding value-based, patient-centered care to the local communities. About the New Partnership...

Continue Reading
Innovative Partnership to Revolutionize Osteoporosis Detection

Updated Category News Views 96

Strategic Alliance to Enhance Osteoporosis Awareness Naitive Technologies Ltd., a leader in population health innovation focused on musculoskeletal care, has embarked on an important partnership with Parvizi Surgical Innovation (PSI). This collaboration aims to significantly improve the detection and clinical management of osteoporosis, particularly through the use of...

Continue Reading
Storm and Fire Survivors Unite at U.S. Capitol for Aid

Updated Category News Views 451

Storm and Fire Survivors Unite at U.S. Capitol for Aid Recently, over fifty storm and fire survivors convened at the U.S. Capitol to advocate for robust disaster relief and a more effective recovery system for affected families and communities, in an event organized by Organizing Resilience. These brave individuals came together to share their compelling stories,...

Continue Reading